Table 1.

Summary of the studies on Razumab

Study name or first author	Type of study	Indications	No of patients/eyes treated	Razumab dose and schedule	BCVA/CDVA	CRT/CMT/CFT/ CSFT
ASSET [55]	Prospective	Wet AMD	126 patients	0.5 mg every 4 weeks for 24 weeks	Baseline: 44 (16.27) letters Week 24: 53.7 (17.83) letters	Baseline: 384.8 ±146.44 µm Week 24: 258.5 ± 74.77 µm
Sameera et al. [2]	Prospective	Wet AMD, DME, RVO	123 eyes of 95 patients	0.5 mg single dose	Baseline: 0.67 ± 0.41 logMAR Day 30: 0.57 ± 0.37 logMAR	Baseline: 345.90 ± 128.84 μm Day 30: 287.66 ± 90.28 μm
Gopal et al. [62]	Retrospective	Wet AMD, DME, RVO	309 eyes of 297 patients	0.5 mg single dose	Baseline: 0.66 ± 0.350 logMAR Day 30: 0.52 ± 0.488 logMAR	Baseline: 400.16 ± 102.360 μm Day 30: 315 ± 87.682 μm
CESAR study [37]	Retrospective	DME, RVO, mCNV	153 eyes of 141 patients	0.5 mg PRN	Baseline: 0.62 ± 0.44 logMAR 3-months: 0.42 ± 0.44 logMAR	Baseline: 405.68 ± 192.422 μm 3-months: 271 ± 104.24 μm
RE-ENACT study [61]	Retrospective	Wet AMD, DME, RVO	561 patients	0.5 mg PRN	Baseline: 0.75 ± 0.01 logMAR Week 12: 0.49 ± 0.01 logMAR	Baseline: 418.47 ± 4.78 μm Week 12: 301.17 ± 2.8 μm
RE-ENACT 2 study [56]	Retrospective	Wet AMD, DME, RVO, mCNV	341 patients	0.5 mg PRN	Baseline: 0.89 ± 0.6 logMAR Week 48: 0.43 ± 0.3 logMAR	Baseline: 467.09 ± 159.6 μm Week 48: 296.56 ± 49.7 μm

AMD Age-related macular degeneration, BCVA best-corrected visual acuity, CDVA corrected distance visual acuity, CFT central foveal thickness, CMT central macular thickness, CRT central retinal thickness, CSFT central subfoveal thickness, DME diabetic macular edema, logMAR logarithm of the minimum angle of resolution, mCNV myopic choroidal neovascularization, PRN pro re nata (as needed), RVO retinal vein occlusion